Krystal Biotech, Inc. (KRYS) Spending and interest coverage
- R&D / revenue · 12 months: Value 13.45%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 12.41%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 13.45% | Research and development expense / revenue. Period ending 2026-06-30. $59.23M ÷ $440.48M × 100 ≈ 13.45% |
| Stock-based compensation / revenue · 12 months | 12.41% | Share-based compensation / revenue. Period ending 2026-06-30. $54.68M ÷ $440.48M × 100 ≈ 12.41% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 59.23M USD | Research and Development Expense |
| Revenue | 440.48M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 54.68M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 197.75M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $59.23M | $440.48M | $54.68M | $197.75M | (m) | 13.45% | 12.41% | (m) | (m) |
| 2026-03-31 | $59.12M | $417.30M | $54.65M | $178.73M | (m) | 14.17% | 13.09% | (m) | (m) |
| 2025-12-31 | $58.05M | $389.13M | $54.51M | $161.29M | (m) | 14.92% | 14.01% | (m) | (m) |
| 2025-09-30 | $56.77M | $373.16M | $54.11M | $158.35M | (m) | 15.21% | 14.50% | (m) | (m) |
| 2025-06-30 | $55.70M | $359.20M | $54.27M | $139.29M | (m) | 15.51% | 15.11% | (m) | (m) |
| 2025-03-31 | $56.87M | $333.45M | $53.31M | $108.56M | (m) | 17.06% | 15.99% | (m) | (m) |
| 2024-12-31 | $53.57M | $290.51M | $49.13M | $65.69M | (m) | 18.44% | 16.91% | (m) | (m) |
| 2024-09-30 | $51.42M | $241.52M | $45.62M | $27.45M | (m) | 21.29% | 18.89% | (m) | (m) |
| 2024-06-30 | $48.54M | $166.23M | $40.62M | $-20.97M | (m) | 29.20% | 24.44% | (m) | (m) |
| 2024-03-31 | $45.10M | $95.95M | $38.80M | $-67.59M | (m) | 47.00% | 40.43% | (m) | (m) |
| 2023-12-31 | $46.43M | $50.70M | $39.93M | $-109.73M | $0.00 | 91.58% | 78.76% | (m) | Reported |
| 2023-09-30 | $45.80M | (m) | $39.63M | $-147.64M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $46.69M | (m) | $40.38M | $-153.09M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $45.44M | (m) | $37.24M | $-143.80M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $42.46M | (m) | $33.23M | $-145.20M | $0.00 | (m) | (m) | (m) | Reported |
| 2022-09-30 | $40.73M | (m) | $28.82M | $-132.30M | $0.00 | (m) | (m) | (m) | Reported |
| 2022-06-30 | $35.29M | (m) | $23.43M | $-116.50M | $0.00 | (m) | (m) | (m) | Reported |
| 2022-03-31 | $31.00M | (m) | $19.44M | $-104.14M | $0.00 | (m) | (m) | (m) | Reported |
| 2021-12-31 | $27.88M | (m) | $15.32M | $-68.28M | $1.49M | (m) | (m) | -45.76× | Reported |
| 2021-09-30 | $24.55M | (m) | $10.74M | $-56.82M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $23.57M | (m) | $8.43M | $-50.85M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $20.61M | (m) | $5.05M | $-41.41M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $17.94M | (m) | $3.27M | $-33.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $16.61M | (m) | $3.02M | $-28.73M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $15.40M | (m) | $1.95M | $-24.39M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $15.97M | (m) | $1.47M | $-23.33M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $15.62M | (m) | $1.24M | $-22.08M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $7.76M | (m) | $792.00K | $-11.92M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $6.05M | (m) | $548.00K | $-9.20M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $5.49M | (m) | $323.00K | $-8.32M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $4.41M | (m) | $220.00K | $-6.58M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $3.21M | (m) | $246.00K | $-4.77M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $741.00K | (m) | $33.00K | $-1.14M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |